Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 29,129 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

NCT05827926
Conditions
SARS-CoV-2, Influenza
Interventions
Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2, mRNA-1083.3, Investigational Influenza Vaccine 1, Investigational COVID-19 Vaccine 1, COVID-19 Vaccine 1, Investigational Influenza Vaccine 2, Influenza Vaccine 2, mRNA-1083, Investigational COVID-19 Vaccine 2, COVID-19 Vaccine 2
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
1,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
69
States / cities
Chandler, Arizona • Colton, California • Huntington Beach, California + 59 more
Completed Phase 2 Interventional Accepts healthy volunteers

Vitamin A Equivalence of Plant Carotenoids in Children

NCT00680212
Conditions
Vitamin A Deficiency
Interventions
dietary carotenoids, spinach, rice, and synthetic beta-carotene
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
6 Years to 8 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
COVID, Sars-CoV2
Interventions
Ivermectin, Camostat Mesilate, Artemesia annua, Artesunate
Drug · Dietary Supplement
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines

NCT03736928
Conditions
Glabellar Frown Lines
Interventions
AbobotulinumtoxinA dose level 1 or 2, placebo, AbobotulinumtoxinA dose 3, AbobotulinumtoxinA dose 4
Biological · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
10
States / cities
Encino, California • Manhattan Beach, California • Vista, California + 7 more
Conditions
Intraprostatic Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
50
States / cities
Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy (5 days), Surgical Resection
Drug · Radiation · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
3
States / cities
San Diego, California • Portland, Oregon
Conditions
Respiratory Syncytial Viruses, Respiratory Tract Diseases
Interventions
RSV Vaccine, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
65 Years and older
Enrollment
5,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
40
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 35 more
Conditions
CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant, Chronic Lymphocytic Leukemia Variants
Interventions
Epcoritamab
Drug
Lead sponsor
Zulfa Omer
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 3 Interventional Results available

Aripiprazole in Adolescents With Schizophrenia

NCT00102063
Conditions
Schizophrenia
Interventions
Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg, Placebo tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 50 more
Conditions
Prostate Cancer
Interventions
Docetaxel, ADT, Abiraterone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Advanced Solid Tumor
Interventions
PEEL-224, FOLF+B
Drug
Lead sponsor
Peel Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Palo Alto, California • Huntersville, North Carolina + 5 more
Conditions
Procedural Sedation, Regional Anesthesia Block, Orthopedic Surgery
Interventions
Fospropofol disodium, Placebo + Midazolam, Fentanyl
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
Interventions
Selinexor
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Months and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation

NCT05721261
Conditions
Nerve Injury
Interventions
Temporary Peripheral Nerve Stimulation System, Sham Temporary Peripheral Nerve Stimulation System
Device
Lead sponsor
Epineuron Technologies Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
6
States / cities
Gainesville, Florida • Orlando, Florida • New Orleans, Louisiana + 3 more
Conditions
Liver Cancer
Interventions
TAC-101
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Erlotinib, Platinum-based chemotherapy
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Conditions
Ovarian Cancer, Malignant Neoplasm of Uterus
Interventions
Sacituzumab, Cisplatin
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
New York, New York
Conditions
Arthritis, Psoriatic
Interventions
JNJ-88545223, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Searcy, Arkansas • Huntington Beach, California • San Diego, California + 15 more
Conditions
Obesity
Interventions
Ribupatide, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
35
States / cities
Mesa, Arizona • Sun City West, Arizona • Irvine, California + 31 more
Conditions
Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myelocytic Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Healthy
Interventions
N91115, Placebo, Placebo-Day 1 only
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado